Portal de Periódicos da CAPES

Antitumor Effect of OK-432–Derived DNA

2006; Lippincott Williams & Wilkins; Volume: 29; Issue: 2 Linguagem: Inglês

10.1097/01.cji.0000189028.18288.6f

1537-4513

Tetsuya Oshikawa, Masato Okamoto, Tomoyuki Tano, Akiko Sasai, Shin Kan, Yoichiro Moriya, Yoshiki Ryoma, Motoo Saito, Shizuo Akira, Mitsunobu Sato,

Cancer therapeutics and mechanisms

OK-432 is a Streptococcus-derived immunotherapeutic agent for malignancies. Our group has tried to identify the effective components of OK-432 and has succeeded in isolating a lipoteichoic acid–related preparation designated as OK-PSA, which is a strong inducer of T helper 1 (TH1) cells, and elicits an anticancer effect via Toll-like receptor (TLR) 4. Conversely, bacterial DNA with unmethylated CpG motifs can stimulate a TH1-type host response via TLR9. The unmethylated CpG DNA contained in OK-432 may play a role in its anticancer effect. In the current study, we investigated the effect of OK-432–derived DNA (OK-DNA) in augmenting the anticancer immune response. Analysis of OK-DNA with the restriction enzymes Hpa II and MspI revealed that OK-DNA contained unmethylated CpG motifs. OK-DNA induced TH1-type cytokines such as interferon-γ, tumor necrosis factor-α, interleukin (IL)-12, and IL-18 and augmented killer cell activities in vitro on human peripheral blood mononuclear cells, whereas the methylated OK-DNA did not. Cytokines were also produced by OK-DNA–stimulated splenocytes derived from wild-type mice but not from TLR9-deficient mice. In the in vivo study, peritumoral administration of OK-DNA resulted in a significant inhibition of tumor growth in syngeneic tumor-bearing wild-type and TLR4-deficient mice but not in TLR9-deficient mice. The antitumor effect of OK-432 in TLR9-deficient mice was significantly but partially reduced compared with that in wild-type mice, whereas the effect of OK-432 was almost completely eliminated in TLR4-deficient mice. These findings suggest that unmethylated CpG DNA in OK-432 functions as an active component in OK-432–induced anticancer immunity via TLR9.